Summary by Moomoo AI
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED THAT ITS HOLDING SUBSIDIARY SHENYANG RED FLAG PHARMACEUTICAL CO., LTD. INDEPENDENTLY DEVELOPED NEW DRUG, CYPRESSINE CAPSULES, HAS RECENTLY BEEN APPROVED FOR LISTING BY THE NATIONAL DRUG ADMINISTRATION. The new drug is primarily used to treat active TB and extrapulmonary tuberculosis, including renal tuberculosis, which respond poorly to first-line anticoagulant drugs. FUSTAR PHARMACEUTICALS EXPECTS THIS NEW DRUG LAUNCH TO PROVIDE MORE OPTIONS FOR TUBERCULOSIS TREATMENT AND FURTHER ENRICH THE COMPANY'S PRODUCT LINE, BUT IS NOT EXPECTED TO HAVE A SIGNIFICANT IMPACT ON PERFORMANCE AT THIS STAGE. THE COMPANY REMINDS INVESTORS THAT DUE TO THE CHARACTERISTICS OF THE PHARMACEUTICAL PRODUCT INDUSTRY, THERE IS UNCERTAINTY IN THE SALES SITUATION OF NEW DRUGS AFTER THE LAUNCH OF NEW DRUGS. THEY ARE MINDFUL OF INVESTMENT RISKS. The announcement date is 24 April 2024.